No material news briefings were available for the 30-day period preceding this report's generation date of 2026-09-19. The most recent prior report on record noted Pfizer's trailing twelve-month revenue as of the second quarter, and the current data set is consistent with that picture. Institutional position changes across multiple major filers served as the primary trigger for this report [Brief - 2026-09-11].
Pfizer's trailing twelve-month revenue stood at $63.70 billion as of 2026-06-28, representing year-over-year growth of approximately 2.6%. Net income over the same period was $4.33 billion, producing a net margin of 6.8%. The operating margin was recorded at 35.19%, while the P/E ratio stood at 36.39. Cash on hand was $976 million against total debt of $63.19 billion. EPS declined 107.84% year-over-year. Gross margin data was not available in the filing period reviewed [SEC 10-Q - PFE - 2026-06-28].
Several institutional filers reported material changes to their PFE positions in the most recent 13F disclosures. Citadel added approximately 15% to its existing position [SEC 13F - Citadel - Q2 2026]. AQR Capital increased its holdings by 56% [SEC 13F - AQR Capital - Q2 2026]. Millennium Management added 28% to its position [SEC 13F - Millennium - Q2 2026]. Bridgewater Associates opened a new position in PFE during the same reporting period [SEC 13F - Bridgewater - Q2 2026]. No insider transaction data was provided for this report period.
The broader interest rate environment shows the 10-year US Treasury yield at 4.94% and the 2-year yield at 4.67%, producing a normal yield curve shape [FRED DGS10; FRED DGS2]. This rate configuration represents the macro backdrop against which Pfizer's debt load of $63.19 billion and financing costs are assessed by the market. The spread between short and long-dated instruments was approximately 27 basis points as of the data available.